Contact
searchSearch
HMP Global

Atopic Dermatitis Feature Story

Feature Story
What’s New in Allergic Contact Dermatitis? 2025’s Allergens on the Rise
05/01/2025
Braily Weber, BS, BA; Sara A. Hylwa, MD
Familiarize yourself with up-and-coming allergens, including their chemical function, role in consumer products, and reported cases of contact allergy.
Familiarize yourself with up-and-coming allergens, including their chemical function, role in consumer products, and reported cases of contact allergy.
Familiarize yourself with...
05/01/2025
The Dermatologist
Emma Guttman-Yassky, MD, PhD
Feature Story
Positive Results Revealed for Atopic Dermatitis Investigational Drug Etrasimod
10/10/2021
Peter Sonnenreich
Recently presented clinical trial data on investigational drug candidate etrasimod, a novel investigational therapy, shows promise for treating moderate to severe atopic dermatitis.
Recently presented clinical trial data on investigational drug candidate etrasimod, a novel investigational therapy, shows promise for treating moderate to severe atopic dermatitis.
Recently presented clinical...
10/10/2021
The Dermatologist
Dupilumab Treatment Provides Multidimensional Improvement of Signs, Symptoms, and Quality of Life in Children With Severe Atopic Dermatitis: A Pictorial Guide
Feature Story
Dupilumab Treatment Provides Multidimensional Improvement of Signs, Symptoms, and Quality of Life in Children With Severe Atopic Dermatitis: A Pictorial Guide
08/13/2020
Ana B. Rossi, MD, CMD; Brad Shumel, MD
This visual 12-patient series by Drs Shumel and Rossi demonstrates the efficacy of dupilumab in patients aged 6 to 11 years with severe atopic dermatitis treated over a 16-week period.
This visual 12-patient series by Drs Shumel and Rossi demonstrates the efficacy of dupilumab in patients aged 6 to 11 years with severe atopic dermatitis treated over a 16-week period.
This visual 12-patient series by...
08/13/2020
The Dermatologist
Feature Story
Tips for Preventing Further Skin Irritation with Adult AD
06/04/2018
Lindsay C. Strowd, MD, FAAD
Personal care products and fabrics can be a major source of potential irritation for people living with atopic dermatitis. In this exclusive series on Tips for Improving Adult Atopic Dermatitis, Lindsay C. Strowd, MD, discusses tips for...
Personal care products and fabrics can be a major source of potential irritation for people living with atopic dermatitis. In this exclusive series on Tips for Improving Adult Atopic Dermatitis, Lindsay C. Strowd, MD, discusses tips for...
Personal care products and...
06/04/2018
The Dermatologist

Popular Articles

Dr Atanaskova-Mesinkovska
Videos
Insights From Fall Clinical: What You Need To Know NOW About Alopecia Areata
09/29/2023
Natasha Atanaskova Mesinkovska, MD, PhD
In this video, Dr Atanaskova-Mesinkovska shares what she’ll be covering during her session, “What You Need To Know NOW About Alopecia Areata,” to be presented at the 2023 Fall Clinical Dermatology Conference.
In this video, Dr Atanaskova-Mesinkovska shares what she’ll be covering during her session, “What You Need To Know NOW About Alopecia Areata,” to be presented at the 2023 Fall Clinical Dermatology Conference.
In this video, Dr...
09/29/2023
The Dermatologist
Fillers
News
Dermal Fillers: Adverse Reactions in Oral and Maxillofacial Regions
12/05/2023
Riya Gandhi, MA
A recent study examines the adverse reactions to dermal fillers in the oral and maxillofacial regions, enhancing the understanding of complications associated with cosmetic procedures.
A recent study examines the adverse reactions to dermal fillers in the oral and maxillofacial regions, enhancing the understanding of complications associated with cosmetic procedures.
A recent study examines the...
12/05/2023
The Dermatologist
Roflumilast Topical Foam
FDA Alerts
Roflumilast Topical Foam, 0.3% Approved for Treatment of Seborrheic Dermatitis
12/18/2023
Jessica Garlewicz
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for...
12/18/2023
The Dermatologist
Derm Dx
What Are These Hyperpigmented Bands on the Fingernails?
02/07/2024
Bijan Safai, MD, DSc; Mehmet Faith Atak, MD; Sumeyye Ozer, MD; Samavia Khan, BS; Banu Farabi, MD
An 83-year-old woman was referred to our clinic with discoloration on her fingernails and toenails.
An 83-year-old woman was referred to our clinic with discoloration on her fingernails and toenails.
An 83-year-old woman was...
02/07/2024
The Dermatologist
psoriatic arthritis
News
Inflammatory Cytokine Changes in Patients With Psoriatic Arthritis Taking TNFα and IL-17A Inhibitors
03/15/2024
Jessica Garlewicz
Researchers investigated changes in biomarker levels among responders and nonresponders to tumor necrosis factor alpha inhibitor (TNFi) and IL-17A inhibitor (IL-17Ai) treatments in patients with psoriatic arthritis.
Researchers investigated changes in biomarker levels among responders and nonresponders to tumor necrosis factor alpha inhibitor (TNFi) and IL-17A inhibitor (IL-17Ai) treatments in patients with psoriatic arthritis.
Researchers investigated changes...
03/15/2024
The Dermatologist

Subscribe

The Dermatologist Newsletter
New Issue - September 2025

Current Issue

September 2025
Volume 33
Issue 6
Current Issue
Issue Archive

Latest Quizzes and Trivia

acne
Quiz
Quiz: Pathophysiologic Pillars of Acne
09/25/2025
Jessica Garlewicz
Which of the following is not 1 of the 4 core pathophysiologic pillars of acne?
Which of the following is not 1 of the 4 core pathophysiologic pillars of acne?
Which of the following is not 1...
09/25/2025
The Dermatologist
psoriasis
Quiz
Quiz: Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
09/25/2025
Jessica Garlewicz
Which of the following clinical features is most strongly associated with an increased risk of developing psoriatic arthritis in patients with psoriasis?
Which of the following clinical features is most strongly associated with an increased risk of developing psoriatic arthritis in patients with psoriasis?
Which of the following clinical...
09/25/2025
The Dermatologist
Quiz
When Should You Start a JAK Inhibitor for AA?
09/22/2025
Riya Gandhi, MA
Clinicians vary in when they escalate to JAK inhibitor therapy for alopecia areata. Take the quiz to see if your threshold aligns with current expert consensus.
Clinicians vary in when they escalate to JAK inhibitor therapy for alopecia areata. Take the quiz to see if your threshold aligns with current expert consensus.
Clinicians vary in when they...
09/22/2025
The Dermatologist
Quiz
Which Systemic Therapy Raises Red Flags in Older Adults?
09/18/2025
Riya Gandhi, MA
Older patients need special consideration. Take the quiz to identify which systemic drug class carries higher risks—like thrombosis and malignancy—and requires extra caution in aging populations.
Older patients need special consideration. Take the quiz to identify which systemic drug class carries higher risks—like thrombosis and malignancy—and requires extra caution in aging populations.
Older patients need special...
09/18/2025
The Dermatologist
Quiz
How Long Before You Call a JAK Inhibitor Non-Responsive?
09/15/2025
Riya Gandhi, MA
What’s the minimum trial duration before judging JAK efficacy in AA? Test your clinical timing.
What’s the minimum trial duration before judging JAK efficacy in AA? Test your clinical timing.
What’s the minimum trial...
09/15/2025
The Dermatologist
Quiz
What’s the Go-To Adjunct With JAKs in AA Regrowth?
09/08/2025
Riya Gandhi, MA
JAK inhibitors are central, but what’s commonly used alongside them in practice to boost hair regrowth? Take the quiz to find out.
JAK inhibitors are central, but what’s commonly used alongside them in practice to boost hair regrowth? Take the quiz to find out.
JAK inhibitors are central, but...
09/08/2025
The Dermatologist
psoriasis
Quiz
NPF Quiz: The Primary Goal of the S.T.R.A.N.D. Network
09/04/2025
Jessica Garlewicz
What is one of the primary goals of the S.T.R.A.N.D. Network as described by Dr Chesahna Kindred?
What is one of the primary goals of the S.T.R.A.N.D. Network as described by Dr Chesahna Kindred?
What is one of the primary goals...
09/04/2025
The Dermatologist
Quiz
Ethical Arguments in AA: Cosmetic vs. Medical
08/21/2025
Explore the ethical flaws in labeling alopecia areata as a cosmetic concern. Take the quiz to uncover the strongest rationale for reclassifying AA as a medical condition.
Explore the ethical flaws in labeling alopecia areata as a cosmetic concern. Take the quiz to uncover the strongest rationale for reclassifying AA as a medical condition.
Explore the ethical flaws in...
08/21/2025
The Dermatologist
psoriasis
Quiz
True or False: TYK2 Inhibition
08/14/2025
Jessica Garlewicz
True or False: TYK2 inhibition blocks IL-12 and IL-23 signaling, both of which contribute to the activation of Th17 cells in psoriasis.
True or False: TYK2 inhibition blocks IL-12 and IL-23 signaling, both of which contribute to the activation of Th17 cells in psoriasis.
True or False: TYK2 inhibition...
08/14/2025
The Dermatologist
alopecia areata
Quiz
Alopecia Areata—JAK Inhibitor Indications
08/14/2025
Jessica Garlewicz
What is the main reason patients on JAK inhibitors for alopecia areata require regular monitoring?
What is the main reason patients on JAK inhibitors for alopecia areata require regular monitoring?
What is the main reason patients...
08/14/2025
The Dermatologist

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use